ArticleBMC genomics2012
Comprehensive analysis of microRNAs in breast cancer.
Article in BMC genomics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 55 citations in OpenAlex.
- Review
- Analyzing the multi-target pharmacological mechanism of foliumAnnals of translational medicine · 2022Article
- RNA uridyl transferases TUT4/7 differentially regulate miRNA variants depending on the cancer cell type.RNA (New York, N.Y.) · 2022Article
- The emerging role of miRNAs in the pathogenesis of COVID-19: Protective effects of nutraceutical polyphenolic compounds against SARS-CoV-2 infection.International journal of medical sciences · 2022Review
- Review
- Circulating miRNAs Act as Diagnostic Biomarkers for Bladder Cancer in Urine.International journal of molecular sciences · 2021Article
- Aberrant miRNAs expressed in HER-2 negative breast cancers patient.Journal of experimental & clinical cancer research : CR · 2018Article
- Comprehensive identification of microRNA arm selection preference in lung cancer: miR-324-5p and -3p serve oncogenic functions in lung cancer.Oncology letters · 2018Article
- Whole blood microRNAs as potential biomarkers in post-operative early breast cancer patients.BMC cancer · 2018Article
- The Challenges and Opportunities in the Clinical Application of Noncoding RNAs: The Road Map for miRNAs and piRNAs in Cancer Diagnostics and Prognostics.International journal of genomics · 2018Review
- MiR-30a-5p Inhibits Epithelial-to-Mesenchymal Transition and Upregulates Expression of Tight Junction Protein Claudin-5 in Human Upper Tract Urothelial Carcinoma Cells.International journal of molecular sciences · 2017Article
- An approach to forecast human cancer by profiling microRNA expressions from NGS data.BMC cancer · 2017Article
- miR-511-3p, embedded in the macrophage mannose receptor gene, contributes to intestinal inflammation.Mucosal immunology · 2016Article
- Arm Selection Preference of MicroRNA-193a Varies in Breast Cancer.Scientific reports · 2016Article
- New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.BMC genomics · 2015Article
- Genetic variant rs16430 6bp > 0bp at the microRNA-binding site in TYMS and risk of sporadic breast cancer risk in non-Hispanic white women aged ≤ 55 years.Molecular carcinogenesis · 2015Article
- bacterial infection drives the expression dynamics of microRNAs and their isomiRs.PLoS genetics · 2015Article
- Entropy-based model for miRNA isoform analysis.PloS one · 2015Article
- Regulation of the mRNA half-life in breast cancer.World journal of clinical oncology · 2014Review
- Principles and methods of integrative genomic analyses in cancer.Nature reviews. Cancer · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 5 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMicroRNAs (miRNAs) are short noncoding RNAs (approximately 22 nucleotides in length) that play important roles in breast cancer progression by downregulating gene expression. The detailed mechanisms and biological functions of miRNA molecules in breast carcinogenesis have yet to be fully elucidated. This study used bioinformatics and experimental approaches to conduct detailed analysis of the dysregulated miRNAs, arm selection preferences, 3' end modifications, and position shifts in isoforms of miRNAs (isomiRs) in breast cancer.
methodsNext-generation sequencing (NGS) data on breast cancer was obtained from the NCBI Sequence Read Archive (SRA). The miRNA expression profiles and isomiRs in normal breast and breast tumor tissues were determined by mapping the clean reads back to human miRNAs. Differences in miRNA expression and pre-miRNA 5p/3p arm usage between normal and breast tumor tissues were further investigated using stem-loop reverse transcription and real-time polymerase chain reaction.
resultsThe analysis identified and confirmed the aberrant expression of 22 miRNAs in breast cancer. Results from pathway enrichment analysis further indicated that the aberrantly expressed miRNAs play important roles in breast carcinogenesis by regulating the mitogen-activated protein kinase (MAPK) signaling pathway. Data also indicated that the position shifts in isomiRs and 3' end modifications were consistent in breast tumor and adjacent normal tissues, and that 5p/3p arm usage of some miRNAs displayed significant preferences in breast cancer.
conclusionsExpression pattern and arm selection of miRNAs are significantly varied in breast cancers through analyzing NGS data and experimental approach. These miRNA candidates have high potential to play critical roles in the progression of breast cancer and could potentially provide as targets for future therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.